TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.
Highlights:
Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.
Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.
This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.
Read more here
Danish biotech start-up Fuse Vectors has launched its R&D operations in Leiden. From its new base at the Leiden Bio Science Park, the company is set to accelerate the...
LUdev is a student-run software company part of the Leiden Institute of Advanced Computer Science (LIACS) of Leiden University. The initiative gives bachelor's students the...
A month after being cleared to sell its animal-free meat fat in the US, Nourish Ingredients has set its sights on the global market with a new commercial hub in the Netherlands....